| 登録番号 | 病名 | レジメン名 | 薬剤名 | 投与量 | 投与日 | 1コース日数 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 04-004 | 胃癌 | CPT-11隔週 | イリノテカン | 150 mg/m$^2$ | D1 | | ● | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | (p.o) アプレピタント | | D1-D3 | 2週毎 | ● | ● | ● | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | (d.i.v) パロノセトロン | 0.75 mg | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | デキサート | 4.95 mg | D1 | | ● | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 04-006 | 胃癌 | PTX | パクリタキセル | 80 mg/m$^2$ | D1、D8、D15 | | ● | | | | | | | ● | | | | | | | ● | | | | | | | | | | | | | 終 | | | | | | | | | | | | | |
| | | | (d.i.v) ガスター | 20 mg | | 4週毎 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | ポララミン | 5 mg | D1、D8、D15 | | ● | | | | | | | ● | | | | | | | ● | | | | | | | | | | | | | 終 | | | | | | | | | | | | | |
| | | | デキサート | 6.6 mg | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 04-007 | 胃癌 | S-1+CDDP | シスプラチン | 60 mg/m$^2$ | D8 | | | | | | | | | ● | | | | | | | | | | | | | | | | | | | | | | | | | | | 終 | | | | | | |
| | | | | 1.25m$^2$未満： | | | | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | | | | | | | | | | | | | | 終 | | | | | | |
| | | | | 80 mg/day | | | | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | | | | | | | | | | | | | | | | | | | |
| | | | S-1 | 1.25-1.5m$^2$未満： | D1-D21 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 終 | | | | | | |
| | | | | 100 mg/day | （D1夕-D22朝） | | | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | | | | | | | | | | | | | | | | | | | |
| | | | | 1.5m$^2$以上： | | | | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | | | | | | | | | | | | | | 終 | | | | | | |
| | | | | 120 mg/day | | 5週毎 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | (p.o) アプレピタント | | D8-D10 | | | | | | | | | ● | ● | ● | | | | | | | | | | | | | | | | | | | | | | | | | | 終 | | | | | | |
| | | | (p.o) デカドロン | 8 mg | D9-D11 | | | | | | | | | | ● | ● | ● | | | | | | | | | | | | | | | | | | | | | | | | | 終 | | | | | | |
| | | | (d.i.v) パロノセトロン | 0.75 mg | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | デキサート | 9.9 mg | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | 硫酸Mg | 20 mEq | D8 | | | | | | | | | ● | | | | | | | | | | | | | | | | | | | | | | | | | | | | 終 | | | | | | |
| | | | フロセミド | 10 mg | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 04-008 | 胃癌 | S-1+CPT-11 | イリノテカン | 80 mg/m$^2$ | D1、D15 | | ● | | | | | | | | | | | | | | ● | | | | | | | | | | | | | | | | | | | | | 終 | | | | | | |
| | | | | 1.25m$^2$未満： | | | | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | | | | | | | | | | | | | | | 終 | | | | | | |
| | | | | 80 mg/day | | | | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | | | | | | | | | | | | | | | | | | | |
| | | | S-1 | 1.25-1.5m$^2$未満： | D1-D21 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 終 | | | | | | |
| | | | | 100 mg/day | （D1夕-D22朝） | 5週毎 | | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | | | | | | | | | | | | | | | | | | | |
| | | | | 1.5m$^2$以上： | | | | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | | | | | | | | | | | | | | | 終 | | | | | | |
| | | | | 120 mg/day | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | (p.o) アプレピタント | | D1-D3 | | ● | ● | ● | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | (d.i.v) パロノセトロン | 0.75 mg | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | デキサート | 4.95 mg | D1 | | ● | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 終 | | | | | | |
| 04-011 | 胃癌 | 術前S-1+CDDP | シスプラチン | 60 mg/m$^2$ | D8 | | | | | | | | | ● | | | | | | | | | | | | | | | | | | | | | | | | | | | 終 | | | | | | |
| | | | | 1.25m$^2$未満： | | | | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | | | | | | | | | | | | | | | 終 | | | | | | |
| | | | | 80 mg/day | | | | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | | | | | | | | | | | | | | | | | | | |
| | | | S-1 | 1.25-1.5m$^2$未満： | D1-D21 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 終 | | | | | | |
| | | | | 100 mg/day | （D1夕-D22朝） | | | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | | | | | | | | | | | | | | | | | | | |
| | | | | 1.5m$^2$以上： | | 4週毎 | | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | | | | | | | | | | | | | | 終 | | | | | | |
| | | | | 120 mg/day | | 術前2クール | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | (p.o) アプレピタント | | D8-D10 | | | | | | | | | ● | ● | ● | | | | | | | | | | | | | | | | | | | | | | | | | | 終 | | | | | | |
| | | | (p.o) デカドロン | 8 mg | D9-D11 | | | | | | | | | | ● | ● | ● | | | | | | | | | | | | | | | | | | | | | | | | | 終 | | | | | | |
| | | | (d.i.v) パロノセトロン | 0.75 mg | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | デキサート | 9.9 mg | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | 硫酸Mg | 20 mEq | D8 | | | | | | | | | ● | | | | | | | | | | | | | | | | | | | | | | | | | | | | 終 | | | | | | |
| | | | フロセミド | 10 mg | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 04-012 | 胃癌 | DOC | ドセタキセル | 60 mg/m$^2$ | | 0 | ● | | | | | | | | | | | | | | | | | | | | | | | | | | | | 終 | | | | | | | | | | | | | |
| | | | (p.o) デカドロン | 8 mg | D1-D3 | 3-4週毎 | ● | ● | ● | | | | | | | | | | | | | | | | | | | | | | | | | | | | 終 | | | | | | | | | | | | | |
| | | | (d.i.v) デキサート | 6.6 mg | D1 | | ● | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 終 | | | | | | | | | | | | | |
| 04-017 | 胃癌 | G-SOX | オキサリプラチン | 100 mg/m$^2$ | D1 | | ● | | | | | | | | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | |
| | | | | 1.25m$^2$未満： | | | | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | |
| | | | | 80 mg/day | | | | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | 朝 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | S-1 | 1.25-1.5m$^2$未満： | D1-D14 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 100 mg/day | （D1夕-D15朝） | | | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | |
| | | | | 1.5m$^2$以上： | | 3週毎 | | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | 夕 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 120 mg/day | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | (p.o) アプレピタント | | D1-D3 | | ● | ● | ● | | | | | | | | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | |
| | | | (p.o) デカドロン | 4 mg | D2-D4 | | | ● | ● | ● | | | | | | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | |
| | | | (d.i.v) パロノセトロン | 0.75 mg | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | ガスター | 20 mg | D1 | | ● | | | | | | | | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | |
| | | | ポララミン | 5 mg | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | デキサート | 4.95 mg | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| 登録番号 | 病名 | レジメン名 | 薬剤名 | 投与量 | 投与日 | 1コース日数 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 04-018 | 胃癌 | G-XELOX | オキサリプラチン | 130 mg/m$^2$ | D1 | | ● | | | | | | | | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | |
| | | | カペシタビン | 1.36m$^2$未満：2400 mg/day<br>1.36-1.66m$^2$未満：3000 mg/day<br>1.66㎡-1.96m$^2$未満：3600 mg/day<br>1.96m$^2$以上：4200 mg/day | D1-D14<br>（D1夕-D15朝） | 3週毎 | | ●朝 | ●朝 | ●朝 | ●朝 | ●朝 | ●朝 | ●朝 | ●朝 | ●朝 | ●朝 | ●朝 | ●朝 | ●朝 | ●朝 | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | ●夕 | ●夕 | ●夕 | ●夕 | ●夕 | ●夕 | ●夕 | ●夕 | ●夕 | ●夕 | ●夕 | ●夕 | ●夕 | ●夕 | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | |
| | | | （p.o）アプレピタント | | D1-D3 | | ● | ● | ● | | | | | | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | |
| | | | （d.i.v）パロノセトロン<br>ガスター<br>ポララミン<br>デキサート | 0.75 mg<br>20 mg<br>5 mg<br>4.95 mg | D1 | | ● | | | | | | | | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | |
| 04-021 | 胃癌 | RAM+PTX | パクリタキセル | 80 mg/m$^2$ | D1、D8、D15 | | ● | | | | | | | ● | | | | | | | ● | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | |
| | | | サイラムザ | 8 mg/kg | D1、D15 | 4 週毎 | ● | | | | | | | | | | | | | | ● | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | |
| | | | （d.i.v）ガスター<br>ポララミン<br>デキサート | 20 mg<br>5 mg<br>6.6 mg | D1、D8、D15 | | ● | | | | | | | ● | | | | | | | ● | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | |
| 04-023 | 胃癌 | オブジーボ | オブジーボ | 240 mg/body | D1 | 2週毎 | ● | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 04-024 | 胃癌 | XP<br>+トラスツズマブBS | シスプラチン | 80 mg/m$^2$ | D1 | | ● | | | | | | | | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | |
| | | | トラスツズマブBS | 初回：8mg/kg<br>2回目以降：6mg/kg | D1 | | ● | | | | | | | | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | |
| | | | カペシタビン | 1.36m$^2$未満：2400 mg/day<br>1.36-1.66m$^2$未満：3000 mg/day<br>1.66㎡-1.96m$^2$未満：3600 mg/day<br>1.96m$^2$以上：4200 mg/day | D1-D14<br>（D1夕-D15朝） | 3週毎<br>6コース | | ●朝 | ●朝 | ●朝 | ●朝 | ●朝 | ●朝 | ●朝 | ●朝 | ●朝 | ●朝 | ●朝 | ●朝 | ●朝 | ●朝 | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | ●夕 | ●夕 | ●夕 | ●夕 | ●夕 | ●夕 | ●夕 | ●夕 | ●夕 | ●夕 | ●夕 | ●夕 | ●夕 | ●夕 | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | |
| | | | （p.o）アプレピタント | | D1-D3 | | ● | ● | ● | | | | | | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | |
| | | | （p.o）デカドロン | 8 mg | D2-D4 | | | ● | ● | ● | | | | | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | |
| | | | （d.i.v）パロノセトロン<br>デキサート<br>硫酸Mg<br>フロセミド | 0.75 mg<br>9.9 mg<br>20 mEq<br>10 mg | D1 | | ● | | | | | | | | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | |
| 04-025 | 胃癌 | トラスツズマブBS<br>維持 | トラスツズマブBS | 6 mg/kg | D1 | 3週毎 | ● | | | | | | | | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | |
| 04-026 | 胃癌 | nabPTX | アブラキサン | 100 mg/m$^2$ | D1、D8、D15 | 4週毎 | ● | | | | | | | ● | | | | | | | ● | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | |
| | | | （d.i.v）デキサート | 6.6 mg | D1、D8、D15 | | ● | | | | | | | ● | | | | | | | ● | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | |
| 04-027 | 胃癌 | XP | シスプラチン | 80 mg/m$^2$ | D1 | | ● | | | | | | | | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | |
| | | | カペシタビン | 1.36m$^2$未満：2400 mg/day<br>1.36-1.66m$^2$未満：3000 mg/day<br>1.66㎡-1.96m$^2$未満：3600 mg/day<br>1.96m$^2$以上：4200 mg/day | D1-D14<br>（D1夕-D15朝） | 3 週毎 | | ●朝 | ●朝 | ●朝 | ●朝 | ●朝 | ●朝 | ●朝 | ●朝 | ●朝 | ●朝 | ●朝 | ●朝 | ●朝 | ●朝 | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | ●夕 | ●夕 | ●夕 | ●夕 | ●夕 | ●夕 | ●夕 | ●夕 | ●夕 | ●夕 | ●夕 | ●夕 | ●夕 | ●夕 | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | |
| | | | （p.o）アプレピタント | | D1-D3 | | ● | ● | ● | | | | | | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | |
| | | | （p.o）デカドロン | 8 mg | D2-D4 | | | ● | ● | ● | | | | | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | |
| | | | （d.i.v）パロノセトロン<br>デキサート<br>硫酸Mg<br>フロセミド | 0.75 mg<br>9.9 mg<br>20 mEq<br>10 mg | D1 | | ● | | | | | | | | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | |
| 04-028 | 胃癌 | RAM+nabPTX | アブラキサン | 100 mg/m$^2$ | D1、D8、D15 | 4週毎 | ● | | | | | | | ● | | | | | | | ● | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | |
| | | | サイラムザ | 8 mg/kg | D1、D15 | | ● | | | | | | | | | | | | | | ● | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | |
| | | | （d.i.v）パロノセトロン<br>ポララミン | 0.75 mg<br>5 mg | D1、D15 | | ● | | | | | | | | | | | | | | ● | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | |
| | | | （d.i.v）デキサート | 6.6 mg | D1、D8、D15 | | ● | | | | | | | ● | | | | | | | ● | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | |

| 登録番号 | 病名 | レジメン名 | 薬剤名 | 投与量 | 投与日 | 1コース日数 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 04-029 | 胃癌 | G-XELOX | オキサリプラチン | 130 mg/m$^2$ | D1 | | ● | | | | | | | | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | |
| | | +トラスツズマブBS | トラスツズマブBS | 初回：8mg/kg<br>2回目以降：6mg/kg | D1 | | ● | | | | | | | | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | |
| | | | カペシタビン | 1.36m$^2$未満：<br>2400 mg/day<br>1.36-1.66m$^2$未満：<br>3000 mg/day<br>1.66㎡-1.96m$^2$未満：<br>3600 mg/day<br>1.96m$^2$以上：<br>4200 mg/day | D1-D14<br>（D1夕-D15朝） | 3週毎 | | ●<br>朝 | ●<br>朝 | ●<br>朝 | ●<br>朝 | ●<br>朝 | ●<br>朝 | ●<br>朝 | ●<br>朝 | ●<br>朝 | ●<br>朝 | ●<br>朝 | ●<br>朝 | ●<br>朝 | ●<br>朝 | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | ●<br>夕 | ●<br>夕 | ●<br>夕 | ●<br>夕 | ●<br>夕 | ●<br>夕 | ●<br>夕 | ●<br>夕 | ●<br>夕 | ●<br>夕 | ●<br>夕 | ●<br>夕 | ●<br>夕 | ●<br>夕 | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | |
| | | | (p.o) アプレピタント | | D1-D3 | | ● | ● | ● | | | | | | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | |
| | | | (d.i.v) パロノセトロン<br>ガスター<br>ポララミン<br>デキサート | 0.75 mg<br>20 mg<br>5 mg<br>4.95 mg | D1 | | ● | | | | | | | | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | |
| 04-030 | 胃癌 | mFOLFOX6 | オキサリプラチン | 85 mg/m$^2$ | D1 | | ● | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | （インフューザーポンプ） | レボホリナート | 200 mg/m$^2$ | D1 | | ● | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | フルオロウラシル | 400 mg/m$^2$ | D1（全開投与） | | ● | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | フルオロウラシル | 2400 mg/m$^2$ | D1（46時間持続） | 2週毎 | ● | ● | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | (p.o) アプレピタント | | D1-D3 | | ● | ● | ● | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | (d.i.v) パロノセトロン<br>ガスター<br>ポララミン<br>デキサート | 0.75 mg<br>20 mg<br>5 m<br>4.95 mg | D1 | | ● | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 04-031 | 胃癌 | S-1+DOC | ドセタキセル | 40 mg/m$^2$ | D1（2-7コース） | | ● | | | | | | | | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | |
| | | | S-1 | 1.25m$^2$未満：<br>80 mg/day<br>1.25-1.5m$^2$未満：<br>100 mg/day<br>1.5m$^2$以上：<br>120 mg/day | 1-7コース：D1-D14<br>8コース以降：D1-D28 | 3週毎<br>8コース以降は6週毎 | | ●<br>朝 | ●<br>朝 | ●<br>朝 | ●<br>朝 | ●<br>朝 | ●<br>朝 | ●<br>朝 | ●<br>朝 | ●<br>朝 | ●<br>朝 | ●<br>朝 | ●<br>朝 | ●<br>朝 | ●<br>朝 | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | ●<br>夕 | ●<br>夕 | ●<br>夕 | ●<br>夕 | ●<br>夕 | ●<br>夕 | ●<br>夕 | ●<br>夕 | ●<br>夕 | ●<br>夕 | ●<br>夕 | ●<br>夕 | ●<br>夕 | ●<br>夕 | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | |
| | | | (p.o) デカドロン | 8 mg | D1-D3 | | ● | ● | ● | | | | | | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | |
| | | | (d.i.v) デキサート | 6.6 mg | D1 | | ● | | | | | | | | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | |
| 04-032 | 胃癌 | オプジーボ | オプジーボ | 480 mg/body | D1 | 4週毎※ | ● | | | | | | | | | | | | | | | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | |
| 04-033 | 胃癌 | G-SOX | オキサリプラチン | 130 mg/m$^2$ | D1 | | ● | | | | | | | | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | |
| | | +オプジーボ | オプジーボ | 360 mg/body | D1 | | ● | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | S-1 | 1.25m$^2$未満：<br>80 mg/day<br>1.25-1.5m$^2$未満：<br>100 mg/day<br>1.5m$^2$以上：<br>120 mg/day | D1-D14<br>（D1夕-D15朝） | 3週毎 | | ●<br>朝 | ●<br>朝 | ●<br>朝 | ●<br>朝 | ●<br>朝 | ●<br>朝 | ●<br>朝 | ●<br>朝 | ●<br>朝 | ●<br>朝 | ●<br>朝 | ●<br>朝 | ●<br>朝 | ●<br>朝 | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | ●<br>夕 | ●<br>夕 | ●<br>夕 | ●<br>夕 | ●<br>夕 | ●<br>夕 | ●<br>夕 | ●<br>夕 | ●<br>夕 | ●<br>夕 | ●<br>夕 | ●<br>夕 | ●<br>夕 | ●<br>夕 | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | |
| | | | (p.o) アプレピタント | | D1-D3 | | ● | ● | ● | | | | | | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | |
| | | | (p.o) デカドロン | 4 mg | D2-D4 | | | ● | ● | ● | | | | | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | |
| | | | (d.i.v) パロノセトロン<br>ガスター<br>ポララミン<br>デキサート | 0.75 mg<br>20 mg<br>5 mg<br>4.95 mg | D1 | | ● | | | | | | | | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | |
| 04-034 | 胃癌 | G-XELOX | オキサリプラチン | 130 mg/m$^2$ | D1 | | ● | | | | | | | | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | |
| | | +オプジーボ | オプジーボ | 360 mg/body | D1 | | ● | | | | | | | | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | |
| | | | カペシタビン | 1.36m$^2$未満：<br>2400 mg/day<br>1.36-1.66m$^2$未満：<br>3000 mg/day<br>1.66㎡-1.96m$^2$未満：<br>3600 mg/day<br>1.96m$^2$以上：<br>4200 mg/day | D1-D14<br>（D1夕-D15朝） | 3週毎 | | ●<br>朝 | ●<br>朝 | ●<br>朝 | ●<br>朝 | ●<br>朝 | ●<br>朝 | ●<br>朝 | ●<br>朝 | ●<br>朝 | ●<br>朝 | ●<br>朝 | ●<br>朝 | ●<br>朝 | ●<br>朝 | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | ●<br>夕 | ●<br>夕 | ●<br>夕 | ●<br>夕 | ●<br>夕 | ●<br>夕 | ●<br>夕 | ●<br>夕 | ●<br>夕 | ●<br>夕 | ●<br>夕 | ●<br>夕 | ●<br>夕 | ●<br>夕 | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | |
| | | | (p.o) アプレピタント | | D1-D3 | | ● | ● | ● | | | | | | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | |
| | | | (d.i.v) パロノセトロン<br>ガスター<br>ポララミン<br>デキサート | 0.75 mg<br>20 mg<br>5 mg<br>4.95 mg | D1 | | ● | | | | | | | | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | |

| 登録番号 | 病名 | レジメン名 | 薬剤名 | 投与量 | 投与日 | 1コース日数 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 04-035 | 胃癌 | mFOLFOX6<br>+オプジーボ<br>（インフューザーポンプ） | オキサリプラチン | 85 mg/m$^2$ | D1 | | ● | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | オプジーボ | 240 mg/body | D1 | | ● | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | レボホリナート | 200 mg/m$^2$ | D1 | | ● | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | フルオロウラシル | 400 mg/m$^2$ | D1（全開投与） | | ● | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | フルオロウラシル | 2400 mg/m$^2$ | D1（46時間持続） | 2週毎 | ● | ● | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | （p.o）アプレピタント | | D1-D3 | | ● | ● | ● | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | （d.i.v）パロノセトロン<br>ガスター<br>ポララミン<br>デキサート | 0.75 mg<br>20 mg<br>5 mg<br>4.95 mg | D1 | | ● | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 04-036 | 胃癌 | サイラムザ<br>+ロンサーフ療法 | サイラムザ | 8 mg/kg | D1、D15 | | ● | | | | | | | | | | | | | | ● | | | | | | | | | | | | | 終 | | | | | | | | | | | | | |
| | | | ロンサーフ | 1.07（㎡）未満：<br>70（mg/day）<br>1.07-1.23未満：80<br>1.23-1.38未満：90<br>1.38-1.53未満：100<br>1.53-1.69未満：110<br>1.69-1.84未満：120<br>1.84-1.99未満：130<br>1.99-2.15未満：140<br>2.15以上：150 | D1-D5、D8-D12 | 4週毎 | ● | ● | ● | ● | ● | | | ● | ● | ● | ● | ● | | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | |
| 04-037 | 胃癌 | ピロイ＋<br>mFOLFOX6療法<br>（インフューザーポンプ） | ピロイ | 初回：800 mg/m$^2$<br>2回目以降：400 mg/m$^2$ | D1 | | ● | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | オキサリプラチン | 85 mg/m$^2$ | D1 | | ● | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | レボホリナート | 200 mg/m$^2$ | D1 | | ● | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | フルオロウラシル | 400 mg/m$^2$ | D1（全開投与） | | ● | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | フルオロウラシル | 2400 mg/m$^2$ | D1（46時間持続） | 2週毎 | ● | ● | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | （p.o）アプレピタント | | D1-D3 | | ● | ● | ● | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | （p.o）オランザピン | 5mg | D1-D4 | | ● | ● | ● | ● | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | （d.i.v）パロノセトロン<br>ガスター<br>ポララミン<br>デキサート | 0.75 mg<br>20 mg<br>5 mg<br>9.9 mg | D1 | | ● | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 04-038 | 胃癌 | ピロイ＋CAPOX療法 | ピロイ | 初回：800 mg/m$^2$<br>2回目以降：600 mg/m$^2$ | D1 | | ● | | | | | | | | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | |
| | | | オキサリプラチン | 130 mg/m$^2$ | D1 | | ● | | | | | | | | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | |
| | | | カペシタビン | 1.36m$^2$未満：<br>2400 mg/day<br>1.36-1.66m$^2$未満：<br>3000 mg/day<br>1.66㎡-1.96m$^2$未満：<br>3600 mg/day<br>1.96m$^2$以上：<br>4200 mg/day | D1-D14<br>（D1夕-D15朝） | 3週毎 | | ●朝 | ●朝 | ●朝 | ●朝 | ●朝 | ●朝 | ●朝 | ●朝 | ●朝 | ●朝 | ●朝 | ●朝 | ●朝 | ●朝 | | | | | | | 終 | | | | | | | | | | | | | | | | | | | |
| | | | | | | | ●夕 | ●夕 | ●夕 | ●夕 | ●夕 | ●夕 | ●夕 | ●夕 | ●夕 | ●夕 | ●夕 | ●夕 | ●夕 | ●夕 | | | | | | | 終 | | | | | | | | | | | | | | | | | | | |
| | | | （p.o）アプレピタント | | D1-D3 | | ● | ● | ● | | | | | | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | |
| | | | （p.o）オランザピン | 5mg | D1-D4 | | ● | ● | ● | ● | | | | | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | |
| | | | （d.i.v）パロノセトロン<br>ガスター<br>ポララミン<br>デキサート | 0.75 mg<br>20 mg<br>5 mg<br>9.9 mg | D1 | | ● | | | | | | | | | | | | | | | | | | | | 終 | | | | | | | | | | | | | | | | | | | |

**2024年7月 更新**

・04-037、04-038追加